You are here: Home » International » News » Others
Business Standard

EU drug watchdog to not set efficacy levels for Covid-19 vaccine approval

The U.S. Food and Drug Administration has said vaccines must demonstrate at least 50% efficacy

European Union | Coronavirus Vaccine

Reuters  |  BRUSSELS 


By Francesco Guarascio

BRUSSELS (Reuters) - Europe's drug regulator will not set a minimum level of efficacy for potential COVID-19 vaccines when considering them for approval, it said on Wednesday, taking a different approach to that of its U.S. counterpart.

Human studies need to demonstrate a convincing level of efficacy, but whether a shot would be considered acceptable for approval will be assessed case by case based on all available data on its safety and efficacy, the European Medicines Agency (EMA) said in an email.

"Therefore it is not possible to specifically quantify in advance the minimum level of efficacy for a vaccine to be considered acceptable for approval," it said.

The U.S. Food and Drug Administration has said vaccines must demonstrate at least 50% efficacy - meaning at least twice as many infections among volunteers who got a placebo as among those in the vaccine group.

The EMA is reviewing candidate vaccines by drug makers Pfizer, AstraZeneca and Moderna under a real-time release process, in an effort to speed up the approval if trials of any of those vaccines are successful. They are undergoing late-stage trials.

The EMA said on Wednesday its human medicines committee (CHMP) is drawing up guidance on its requirements for COVID-19 vaccine approval and will publish the information as soon as it is ready.


(Reporting by Francesco Guarascio in Brussels @fraguarascio; Writing by Josephine Mason in London, editing by Emelia Sithole-Matarise)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, November 04 2020. 22:35 IST